The SCV Vaccine Platform has applications across four key market domains each with significant and growing markets
Infectious Disease
~$72bn TAM (CAGR +8%)
Chronic Disease
~$7bn TAM
(CAGR +17.7%)
Animal Health
$10bn TAM (CAGR +6.5%)
Adjunct Technology
~$1bn TAM
(CAGR 11%)
The SCV Vaccine has broad Utility
Combination Vaccines
Leveraging the capacity of SCV to accommodate a large antigen payload within its genome, the SCV Vaccine Platform can be used to generate a combination vaccine against two or more pathogens.
Vaccines with Hostile Antigens
Proprietary technology enables SCV Vaccines containing hostile, cytotoxic or unstable antigens to be constructed and manufactured without impacting quality or yield.
Vaccines with Multiple Immunogens
Leveraging the capacity of SCV to accommodate a large antigen payload within its genome, the SCV Vaccine Platform can be used to generate complex vaccines that can target multiple elements of a single pathogen.
Immune Modulation
SCV vaccines leverage the established safety and immunogenicity of vaccinia viral vectors to trigger a Th1 immune response, facilitating an immune response switch and inducing immune tolerance.
Gene Therapy / Delivery
SCV vaccines can be a versatile delivery vehicle for therapeutic gene products. High levels of transgene expression can be temporarily achieved without integration into the host genome or virus replication.
Positioned for Rapid Response to New and Emerging Infectious Disease
The SCV Vaccine Platform has been designed to deliver safe, versatile and scale-able vaccines and is being positioned for new vaccine readiness within 100 days of pandemic pathogen antigen identification – an alternative to mRNA technology.
However, unlike most other vaccine platforms the broad utility and platform “plug and play” functionality the SCV Vaccine Platform has the potential to address Disease X.
Additional unique opportunities have been identified
Pan-family eg. pan-filovirus, orthopox
Multi-strain eg. Universal flu
Multi-disease